

Mohammad Shadab Siddiqui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1145468/publications.pdf>

Version: 2024-02-01

72
papers

3,389
citations

186265
28
h-index

155660
55
g-index

73
all docs

73
docs citations

73
times ranked

4078
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. Clinical Gastroenterology and Hepatology, 2023, 21, 45-54.e6.	4.4	29
2	An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clinical Gastroenterology and Hepatology, 2023, 21, 619-629.e7.	4.4	90
3	Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clinical Gastroenterology and Hepatology, 2023, 21, 445-455.e2.	4.4	13
4	Interplay Between Dyslipidemia, Atherogenic Lipoproteins, and Residual Atherogenic Risk in Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2023, 21, 1660-1662.e1.	4.4	2
5	A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2462-2473.e10.	4.4	59
6	Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. Endocrine Practice, 2022, 28, 223-230.	2.1	31
7	A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. Liver Transplantation, 2022, 28, 689-699.	2.4	15
8	A Diagnostic Test Meta-Analysis Evaluating Imaging-Based and Blood Biomarker-Based Assessment Tools for Fibrosis After Liver Transplantation. Liver Transplantation, 2022, 28, 659-669.	2.4	6
9	Early laboratory values after liver transplantation are associated with anastomotic biliary strictures. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, 76-83.	0.1	2
10	Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2022, 55, 483-484.	3.7	1
11	Differential fuel utilization in liver transplant recipients and its relationship with non-alcoholic fatty liver disease. Liver International, 2022, 42, 1401-1409.	3.9	8
12	Glomerular filtration rate early after liver transplantation independently predicts atherosclerotic events. Liver Transplantation, 2022, 28, 1186-1195.	2.4	4
13	Performance of Vibration-Controlled Transient Elastography and Clinical Prediction Models In Liver Transplant Recipients. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	1
14	Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. Clinical and Molecular Hepatology, 2022, 28, 483-496.	8.9	49
15	Meta-Analysis: analysis of mechanistic pathways in the treatment of <sc>non-alcoholic</sc> steatohepatitis. Evidence from a Bayesian network <sc>meta-analysis</sc>. Alimentary Pharmacology and Therapeutics, 2022, 55, 1076-1087.	3.7	15
16	Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hepatology International, 2022, 16, 269-281.	4.2	23
17	Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12â€‰%620â€‰%736 Individuals. Endocrine Practice, 2022, 28, 667-672.	2.1	34
18	Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncology, The, 2022, 23, 521-530.	10.7	116

#	ARTICLE	IF	CITATIONS
19	A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. <i>Digestive and Liver Disease</i> , 2022, 54, 614-621.	0.9	11
20	Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	2.5	20
21	Sex Differences in Vascular Endothelial Function After Liver Transplant. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
22	Weight Gain, Fibroblast Growth Factor-23, and Vascular Function in Liver Transplant Recipients. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
23	Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2202-2204.	4.4	7
24	A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2670-2672.	4.4	41
25	Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. <i>Digestive Diseases and Sciences</i> , 2021, 66, 263-272.	2.3	11
26	Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 367-374.	4.4	33
27	Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications. <i>Liver Transplantation</i> , 2021, 27, 1326-1333.	2.4	6
28	A meta-analysis of the cumulative incidence, risk factors, and clinical outcomes associated with chronic kidney disease after liver transplantation. <i>Transplant International</i> , 2021, 34, 2524-2533.	1.6	6
29	Office-Based Weight Loss Counseling Is Ineffective in Liver Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 639-646.	2.3	9
30	Reply. <i>Hepatology</i> , 2020, 71, 401-402.	7.3	0
31	Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 72, 25-33.	3.7	88
32	Clopidogrel Responsiveness in Patients With Decompensated Cirrhosis of the Liver Undergoing Pre-Transplant PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 661-663.	2.9	7
33	The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00127.	2.4	15
34	Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2020, 11, 592373.	3.5	42
35	Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 619-636.	3.7	6
36	Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, xiii-xiv.	2.2	0

#	ARTICLE	IF	CITATIONS
37	Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 165-178.	2.2	3
38	The Impact of Coronary Artery Disease and Statins on Survival After Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1514-1523.	2.4	46
39	Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019, 9, 12541.	3.3	106
40	Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 1895-1901.	0.6	6
41	Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients. <i>Hepatology</i> , 2019, 70, 98-107.	7.3	29
42	Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2132-2133.	4.4	12
43	<p>Obesity paradox in cardiovascular disease: where do we stand?</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 89-100.	2.3	234
44	Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. <i>Hepatology</i> , 2019, 70, 1690-1703.	7.3	196
45	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1877-1885.e5.	4.4	145
46	Editorial: ascitic cholesterol is it superior to serum ascites albumin gradient?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 814-815.	3.7	1
47	The relationship between coronary artery disease and cardiovascular events early after liver transplantation. <i>Liver International</i> , 2019, 39, 1363-1371.	3.9	30
48	The Relationship Between Hypoadiponectinemia and Cardiovascular Events in Liver Transplant Recipients. <i>Transplantation</i> , 2019, 103, 2323-2328.	1.0	12
49	Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. <i>Drugs</i> , 2019, 79, 75-84.	10.9	17
50	Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS0200) on Weight and Metabolic Parameters. <i>Obesity</i> , 2019, 27, 59-67.	3.0	18
51	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	4.4	322
52	The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease. <i>Hepatology</i> , 2019, 69, 1372-1374.	7.3	14
53	Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance. <i>American Journal of Cardiology</i> , 2019, 123, 466-473.	1.6	36
54	Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. <i>JCI Insight</i> , 2019, 4, .	5.0	49

#	ARTICLE	IF	CITATIONS
55	Adherence to Recommended Inpatient Hepatic Encephalopathy Workup. Journal of Hospital Medicine, 2019, 14, 157-160.	1.4	15
56	Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation. Liver Transplantation, 2018, 24, 872-880.	2.4	43
57	Reply. Liver Transplantation, 2018, 24, 978-979.	2.4	0
58	Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transplantation, 2018, 24, 333-342.	2.4	78
59	Treatment of HCV in the Department of Corrections in the Era of Oral Medications. Journal of Correctional Health Care, 2018, 24, 127-136.	0.5	29
60	The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology, 2018, 67, 534-548.	7.3	266
61	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	7.3	125
62	Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology, 2018, 67, 134-144.	7.3	192
63	Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1177-1186.	0.4	98
64	Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease. Thrombosis Research, 2017, 150, 41-43.	1.7	5
65	Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. Transplantation, 2017, 101, 1867-1874.	1.0	112
66	Endoscopic Cyanoacrylate Injection with Post-injection Audible Doppler Assessment of Gastric Varices: A Single-Institution Experience. Digestive Diseases and Sciences, 2017, 62, 3091-3099.	2.3	3
67	Non-alcoholic Fatty Liver Disease in Non-obese Patients. Current Hepatology Reports, 2017, 16, 382-390.	0.9	0
68	Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease. Liver International, 2016, 36, 572-579.	3.9	38
69	Preserved hemostatic status in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 65, 980-987.	3.7	72
70	The etiology of cirrhosis is a strong determinant of brain reserve: A multimodal magnetic resonance imaging study. Liver Transplantation, 2015, 21, 1123-1132.	2.4	45
71	Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β^2 -Cell) Function. Digestive Diseases and Sciences, 2015, 60, 2529-2537.	2.3	28
72	Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile. Clinical Gastroenterology and Hepatology, 2015, 13, 1000-1008.e3.	4.4	164